MeSH D002056 - burns
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D014947:Wounds and injuries
D002056:Â
Burns
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Lidocaine, Prilocaine | Emla |  | 1992-12-30 |  |  |
| Lidocaine | Lidocaine |  | 2018-01-16 |  |  | |
| Padagis | Lidocaine, Prilocaine | Lidocaine Prilocaine |  | 2021-07-27 |  |  |
| Taro Pharmaceutical | Lidocaine | Lidocaine |  | 1982-01-01 |  |  |
| Lidocaine, Tetracaine | Pliaglis | 2031-01-14 | 2006-06-29 |  |  | |
| Glenmark Pharmaceuticals | Lidocaine | Lidocaine |  | 2016-09-09 |  |  |
| Rising Pharmaceuticals | Lidocaine | Lidocaine |  | 2010-09-27 |  |  |
| Mylan | Lidocaine | Lidocaine |  | 2015-08-07 |  |  |
| Roche | Ceftriaxone, Lidocaine | Rocephin |  | 1984-12-21 | $261.442 M | Y2021 |
| AstraZeneca | Lidocaine, Prilocaine | Emla |  | 1998-02-04 |  |  |
| Lidocaine | Xylocaine |  | 1982-01-01 |  |  | |
| Lidocaine, Epinephrine | Xylocaine W/ Epinephrine |  | 1982-01-01 |  |  | |
| Lidocaine | Xylocaine W/ Glucose |  | 1982-07-07 |  |  | |
| Novartis | Heparin, Lidocaine, Dihydroergotamine | Embolex |  | 1984-11-30 |  |  |
1
2
3
4
5
6
...
10
>
Clinical Trials
Historical Success Rate
Phase 1
64%9/14
Phase 2
64%27/42
Phase 3
33%19/57
Approved: 7Overall Success rate: 14%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
6
7
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use